The endothelial glycocalyx as a potential modifier of the hemolytic uremic syndrome

European Journal of Internal Medicine

Volumn 24, Issue 6, 2013, Pages 503-509

  Boels, Margien G S ^a   Lee, Dae Hyun ^a   Van Den Berg, Bernard M ^a   Dane, Martijn J C ^a   Van Der Vlag, Johan ^b   Rabelink, Ton J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atypical hemolytic uremic syndrome; Complement factor H; Glycocalyx; Heparan sulfate proteoglycan; Thrombomodulin

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; ANTITHROMBIN III; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; GLYCOPROTEIN; GLYCOSAMINOGLYCAN; GLYPICAN; HEPARAN SULFATE; HERMES ANTIGEN; N ACETYLGLUCOSAMINE; PERLECAN; PROTEOGLYCAN; REGULATOR PROTEIN; SULODEXIDE; SYNDECAN; THROMBIN; THROMBOMODULIN; VERSICAN;

CELL HETEROGENEITY; CELL PROTECTION; CELL STRUCTURE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG TARGETING; GENE MUTATION; GENETIC ASSOCIATION; GLYCOCALYX; HEMOLYTIC UREMIC SYNDROME; HOMEOSTASIS; HUMAN; INNATE IMMUNITY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS TYPE 2; MICROVASCULAR ENDOTHELIAL CELL; MOLECULAR RECOGNITION; PATHOGENESIS; PENETRANCE; REVIEW;

ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT FACTOR H; GLYCOCALYX; HEPARAN SULFATE PROTEOGLYCAN; THROMBOMODULIN;

COMPLEMENT ACTIVATION; COMPLEMENT FACTOR H; ENDOTHELIUM, VASCULAR; GENETIC PREDISPOSITION TO DISEASE; GLYCOCALYX; HEMOLYTIC-UREMIC SYNDROME; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; THROMBOMODULIN;

EID: 84883552294     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2012.12.016     Document Type: Review

References (117)

1. M. Noris, and G. Remuzzi Hemolytic uremic syndrome J Am Soc Nephrol 16 2005 1035 1050 (Pubitemid 41710314)
2. N. Besbas, D. Karpman, D. Landau, C. Loirat, W. Proesmans, and G. Remuzzi A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders Kidney Int 70 2006 423 431 (Pubitemid 44141568)
3. A.R. Constantinescu, M. Bitzan, L.S. Weiss, E. Christen, B.S. Kaplan, and A. Cnaan Non-enteropathic hemolytic uremic syndrome: causes and short-term course Am J Kidney Dis 43 2004 976 982 (Pubitemid 38691492)
4. D. Westra, J.F. Wetzels, E.B. Volokhina, L.P. Van Den Heuvel, and N.C. van De Kar A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome Neth J Med 70 2012 121 129
5. M. Noris, J. Caprioli, E. Bresin, C. Mossali, G. Pianetti, and S. Gamba Relative role of genetic complement abnormalities in sporadic and familial a HUS and their impact on clinical phenotype Clin J Am Soc Nephrol 5 2010 1844 1859
6. D. Ricklin, G. Hajishengallis, K. Yang, and J.D. Lambris Complement: a key system for immune surveillance and homeostasis Nat Immunol 11 2010 785 797
7. D.S. Cole, and B.P. Morgan Beyond lysis: how complement influences cell fate Clin Sci (Lond) 104 2003 455 466 (Pubitemid 36628141)
8. K.S. Kilgore, E. Schmid, T.P. Shanley, C.M. Flory, V. Maheswari, and N.L. Tramontini Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation Am J Pathol 150 1997 2019 2031 (Pubitemid 27233075)
9. F. Niculescu, and H. Rus Mechanisms of signal transduction activated by sublytic assembly of terminal complement complexes on nucleated cells Immunol Res 24 2001 191 199 (Pubitemid 32897078)
10. M.K. Pangburn Cutting edge: localization of the host recognition functions of complement factor H at the carboxyl-terminal: implications for hemolytic uremic syndrome J Immunol 169 2002 4702 4706 (Pubitemid 35217129)
11. M. Noris, and G. Remuzzi Atypical hemolytic-uremic syndrome N Engl J Med 361 2009 1676 1687
12. S.J. Clark, P.N. Bishop, and A.J. Day Complement factor H and age-related macular degeneration: the role of glycosaminoglycan recognition in disease pathology Biochem Soc Trans 38 2010 1342 1348
13. A.J. Day, S.J. Clark, and P.N. Bishop Understanding the molecular basis of age-related macular degeneration and how the identification of new mechanisms may aid the development of novel therapies Expert Rev Ophthalmol 6 2011 123 128
14. R.J. Smith, J. Alexander, P.N. Barlow, M. Botto, T.L. Cassavant, and H.T. Cook New approaches to the treatment of dense deposit disease J Am Soc Nephrol 18 2007 2447 2456 (Pubitemid 47378860)
15. M. Gouverneur, B. Berg, M. Nieuwdorp, E. Stroes, and H. Vink Vasculoprotective properties of the endothelial glycocalyx: effects of fluid shear stress J Intern Med 259 2006 393 400 (Pubitemid 43384230)
16. A. Singh, S.C. Satchell, C.R. Neal, E.A. McKenzie, J.E. Tooke, and P.W. Mathieson Glomerular endothelial glycocalyx constitutes a barrier to protein permeability J Am Soc Nephrol 18 2007 2885 2893 (Pubitemid 350058395)
17. B.M. Van Den Berg, H. Vink, and J.A. Spaan The endothelial glycocalyx protects against myocardial edema Circ Res 92 2003 592 594 (Pubitemid 36417691)
18. B.M. Van Den Berg, J.A. Spaan, and H. Vink Impaired glycocalyx barrier properties contribute to enhanced intimal low-density lipoprotein accumulation at the carotid artery bifurcation in mice Pflugers Arch 457 2009 1199 1206
19. J.A. Florian, J.R. Kosky, K. Ainslie, Z. Pang, R.O. Dull, and J.M. Tarbell Heparan sulfate proteoglycan is a mechanosensor on endothelial cells Circ Res 93 2003 e136 e142
20. S. Weinbaum, X. Zhang, Y. Han, H. Vink, and S.C. Cowin Mechanotransduction and flow across the endothelial glycocalyx Proc Natl Acad Sci U S A 100 2003 7988 7995 (Pubitemid 36760082)
21. M.Y. Pahakis, J.R. Kosky, R.O. Dull, and J.M. Tarbell The role of endothelial glycocalyx components in mechanotransduction of fluid shear stress Biochem Biophys Res Commun 355 2007 228 233 (Pubitemid 46273392)
22. J.M. Tarbell, and E.E. Ebong The endothelial glycocalyx: a mechano-sensor and -transducer Sci Signal 1 2008
23. A.A. Constantinescu, H. Vink, and J.A. Spaan Endothelial cell glycocalyx modulates immobilization of leukocytes at the endothelial surface Arterioscler Thromb Vasc Biol 23 2003 1541 1547 (Pubitemid 37108195)
24. A.L. Rops, M.J. Van Den Hoven, M.M. Baselmans, J.F. Lensen, T.J. Wijnhoven, and L.P. Van Den Heuvel Heparan sulfate domains on cultured activated glomerular endothelial cells mediate leukocyte trafficking Kidney Int 73 2008 52 62 (Pubitemid 350273635)
25. A.W. Mulivor, and H.H. Lipowsky Role of glycocalyx in leukocyte-endothelial cell adhesion Am J Physiol Heart Circ Physiol 283 2002 H1282 H1291
26. D. Chappell, N. Dorfler, M. Jacob, M. Rehm, U. Welsch, and P. Conzen Glycocalyx protection reduces leukocyte adhesion after ischemia/reperfusion Shock 34 2010 133 139
27. S. Reitsma, M.G. Oude Egbrink, V.V. Heijnen, R.T. Megens, W. Engels, and H. Vink Endothelial glycocalyx thickness and platelet-vessel wall interactions during atherogenesis Thromb Haemost 106 2011 939 946
28. H. Vink, A.A. Constantinescu, and J.A. Spaan Oxidized lipoproteins degrade the endothelial surface layer: implications for platelet-endothelial cell adhesion Circulation 101 2000 1500 1502 (Pubitemid 30180883)
29. B.A. Lemkes, M. Nieuwdorp, J.B. Hoekstra, and F. Holleman The glycocalyx and cardiovascular disease in diabetes: should we judge the endothelium by its cover? Diabetes Technol Ther 14 2012 S3 S10
30. M.I. Noble, A.J. Drake-Holland, and H. Vink Hypothesis: arterial glycocalyx dysfunction is the first step in the atherothrombotic process QJM 101 2008 513 518 (Pubitemid 351911993)
31. E.P. Schmidt, Y. Yang, W.J. Janssen, A. Gandjeva, M.J. Perez, and L. Barthel The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis Nat Med 18 2012 1217
32. A.W. Mulivor, and H.H. Lipowsky Inflammation- and ischemia-induced shedding of venular glycocalyx Am J Physiol Heart Circ Physiol 286 2004 H1672 H1680
33. I. Rubio-Gayosso, S.H. Platts, and B.R. Duling Reactive oxygen species mediate modification of glycocalyx during ischemia-reperfusion injury Am J Physiol Heart Circ Physiol 290 2006 H2247 H2256
34. M. Rehm, D. Bruegger, F. Christ, P. Conzen, M. Thiel, and M. Jacob Shedding of the endothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia Circulation 116 2007 1896 1906 (Pubitemid 350287085)
35. B. Van Den Berg, and H. Vink Glycocalyx perturbation: cause or consequence of damage to the vasculature? Am J Physiol Heart Circ Physiol 290 2006 H2174 H2175
36. S. Reitsma, D.W. Slaaf, H. Vink, M.A. van Zandvoort, and M.G. oude Egbrink The endothelial glycocalyx: composition, functions, and visualization Pflugers Arch 454 2007 345 359 (Pubitemid 46742429)
37. S. Weinbaum, J.M. Tarbell, and E.R. Damiano The structure and function of the endothelial glycocalyx layer Annu Rev Biomed Eng 9 2007 121 167 (Pubitemid 350246654)
38. J.D. Esko, and S.B. Selleck Order out of chaos: assembly of ligand binding sites in heparan sulfate Annu Rev Biochem 71 2002 435 471 (Pubitemid 34800227)
39. A.L. Rops, J. van der Vlag, J.F. Lensen, T.J. Wijnhoven, L.P. Van Den Heuvel, and T.H. van Kuppevelt Heparan sulfate proteoglycans in glomerular inflammation Kidney Int 65 2004 768 785 (Pubitemid 38251053)
40. K. Uchimura, M. Morimoto-Tomita, A. Bistrup, J. Li, M. Lyon, and J. Gallagher HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1 BMC Biochem 7 2006 2
41. J.D. Esko, and U. Lindahl Molecular diversity of heparan sulfate J Clin Invest 108 2001 169 173 (Pubitemid 32656238)
42. J.F. Lensen, A.L. Rops, T.J. Wijnhoven, T. Hafmans, W.F. Feitz, and E. Oosterwijk Localization and functional characterization of glycosaminoglycan domains in the normal human kidney as revealed by phage display-derived single chain antibodies J Am Soc Nephrol 16 2005 1279 1288 (Pubitemid 41716512)
43. M. Maccarana, Y. Sakura, A. Tawada, K. Yoshida, and U. Lindahl Domain structure of heparan sulfates from bovine organs J Biol Chem 271 1996 17804 17810 (Pubitemid 26250756)
44. H. Tekotte, M. Engel, R.U. Margolis, and R.K. Margolis Disaccharide composition of heparan sulfates: brain, nervous tissue storage organelles, kidney, and lung J Neurochem 62 1994 1126 1130 (Pubitemid 24064528)
45. J. Van Den Born, L.P. Van Den Heuvel, M.A. Bakker, J.H. Veerkamp, K.J. Assmann, and J.H. Berden Monoclonal antibodies against the protein core and glycosaminoglycan side chain of glomerular basement membrane heparan sulfate proteoglycan: characterization and immunohistological application in human tissues J Histochem Cytochem 42 1994 89 102 (Pubitemid 24006637)
46. N.C. Smits, S. Kurup, A.L. Rops, G.B. ten Dam, L.F. Massuger, and T. Hafmans The heparan sulfate motif (GlcNS6S-IdoA2S)3, common in heparin, has a strict topography and is involved in cell behavior and disease J Biol Chem 285 2010 41143 41151
47. L. Wang, M. Fuster, P. Sriramarao, and J.D. Esko Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses Nat Immunol 6 2005 902 910 (Pubitemid 43090445)
48. K.H. Olie, T.H. Goodship, R. Verlaak, S. Florquin, J.W. Groothoff, and L. Strain Posttransplantation cytomegalovirus-induced recurrence of atypical hemolytic uremic syndrome associated with a factor H mutation: successful treatment with intensive plasma exchanges and ganciclovir Am J Kidney Dis 45 2005 e12 e15
49. R. Berner, M.F. Krause, N. Gordjani, P.F. Zipfel, N. Boehm, and M. Krueger Hemolytic uremic syndrome due to an altered factor H triggered by neonatal pertussis Pediatr Nephrol 17 2002 190 192 (Pubitemid 36076035)
50. J. Acosta, J. Hettinga, R. Fluckiger, N. Krumrei, A. Goldfine, and L. Angarita Molecular basis for a link between complement and the vascular complications of diabetes Proc Natl Acad Sci U S A 97 2000 5450 5455 (Pubitemid 30313739)
51. Y. Cheng, and M. Gao The effect of glycation of CD59 on complement-mediated cytolysis Cell Mol Immunol 2 2005 313 317
52. J.N. George, S.K. Vesely, and D.R. Terrell The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS Semin Hematol 41 2004 60 67 (Pubitemid 38057786)
53. T.S. Jokiranta, P.F. Zipfel, V. Fremeaux-Bacchi, C.M. Taylor, T.J. Goodship, and M. Noris Where next with atypical hemolytic uremic syndrome? Mol Immunol 44 2007 3889 3900 (Pubitemid 47337120)
54. J. Esparza-Gordillo, E. Goicoechea De Jorge, A. Buil, L. Carreras Berges, M. Lopez-Trascasa, and P. Sanchez-Corral Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32 Hum Mol Genet 14 2005 703 712 (Pubitemid 40309595)
55. V. Fremeaux-Bacchi, E.J. Kemp, J.A. Goodship, M.A. Dragon-Durey, L. Strain, and C. Loirat The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts J Med Genet 42 2005 852 856 (Pubitemid 41598193)
56. H. Kerr, and A. Richards Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndrome Immunobiology 217 2012 195 203
57. P.F. Zipfel, S. Heinen, M. Jozsi, and C. Skerka Complement and diseases: defective alternative pathway control results in kidney and eye diseases Mol Immunol 43 2006 97 106 (Pubitemid 41021526)
58. H.P. Morgan, C.Q. Schmidt, M. Guariento, B.S. Blaum, D. Gillespie, and A.P. Herbert Structural basis for engagement by complement factor H of C3b on a self surface Nat Struct Mol Biol 18 2011 463 470
59. J. Ripoche, A.J. Day, A.C. Willis, K.T. Belt, R.D. Campbell, and R.B. Sim Partial characterization of human complement factor H by protein and cDNA sequencing: homology with other complement and non-complement proteins Biosci Rep 6 1986 65 72 (Pubitemid 16102528)
60. M.J. Lehtinen, A.L. Rops, D.E. Isenman, J. van der Vlag, and T.S. Jokiranta Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome J Biol Chem 284 2009 15650 15658
61. A. Richards, M.R. Buddles, R.L. Donne, B.S. Kaplan, E. Kirk, and M.C. Venning Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition Am J Hum Genet 68 2001 485 490 (Pubitemid 32147817)
62. M.D. Kazatchkine, D.T. Fearon, J.E. Silbert, and K.F. Austen Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b J Exp Med 150 1979 1202 1215 (Pubitemid 10249943)
63. C.Q. Schmidt, A.P. Herbert, D. Kavanagh, C. Gandy, C.J. Fenton, and B.S. Blaum A new map of glycosaminoglycan and C3b binding sites on factor H J Immunol 181 2008 2610 2619
64. S. Meri, and M.K. Pangburn Regulation of alternative pathway complement activation by glycosaminoglycans: specificity of the polyanion binding site on factor H Biochem Biophys Res Commun 198 1994 52 59 (Pubitemid 24172719)
65. T. Manuelian, J. Hellwage, S. Meri, J. Caprioli, M. Noris, and S. Heinen Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome J Clin Invest 111 2003 1181 1190 (Pubitemid 36519935)
66. S.J. Clark, R. Perveen, S. Hakobyan, B.P. Morgan, R.B. Sim, and P.N. Bishop Impaired binding of the age-related macular degeneration-associated complement factor H 402H allotype to Bruch's membrane in human retina J Biol Chem 285 2010 30192 30202
67. S.J. Clark, T.D. Keenan, H.L. Fielder, L.J. Collinson, R.J. Holley, and C.L. Merry Mapping the differential distribution of glycosaminoglycans in the adult human retina, choroid, and sclera Invest Ophthalmol Vis Sci 52 2011 6511 6521
68. A.P. Herbert, D. Kavanagh, C. Johansson, H.P. Morgan, B.S. Blaum, and J.P. Hannan Structural and functional characterization of the product of disease-related factor H gene conversion Biochemistry 51 2012 1874 1884
69. M.K. Pangburn, N. Rawal, C. Cortes, M.N. Alam, V.P. Ferreira, and M.A. Atkinson Polyanion-induced self-association of complement factor H J Immunol 182 2009 1061 1068
70. M. Noris, F. Mescia, and G. Remuzzi STEC-HUS, atypical HUS and TTP are all diseases of complement activation Nat Rev Nephrol 8 2012 622 633
71. D. Orth, and R. Wurzner Complement in typical hemolytic uremic syndrome Semin Thromb Hemost 36 2010 620 624
72. D. Orth, A.B. Khan, A. Naim, K. Grif, J. Brockmeyer, and H. Karch Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome J Immunol 182 2009 6394 6400
73. J. Geelen, F. Valsecchi, T. van der Velden, L. Van Den Heuvel, L. Monnens, and M. Morigi Shiga-toxin-induced firm adhesion of human leukocytes to endothelium is in part mediated by heparan sulfate Nephrol Dial Transplant 23 2008 3091 3095
74. L. Gu, H. Wang, Y.L. Guo, and K. Zen Heparin blocks the adhesion of E. coli O157:H7 to human colonic epithelial cells Biochem Biophys Res Commun 369 2008 1061 1064
75. A. Atkinson, S. Garnier, S. Afridi, F. Fumoux, and P. Rihet Genetic variations in genes involved in heparan sulphate biosynthesis are associated with Plasmodium falciparum parasitaemia: a familial study in Burkina Faso Malar J 11 2012 108
76. M.D. Bobardt, P. Salmon, L. Wang, J.D. Esko, D. Gabuzda, and M. Fiala Contribution of proteoglycans to human immunodeficiency virus type 1 brain invasion J Virol 78 2004 6567 6584 (Pubitemid 38715954)
77. M. Huber-Lang, J.V. Sarma, F.S. Zetoune, D. Rittirsch, T.A. Neff, and S.R. McGuire Generation of C5a in the absence of C3: a new complement activation pathway Nat Med 12 2006 682 687 (Pubitemid 43865238)
78. M.J. Krisinger, V. Goebeler, Z. Lu, S.C. Meixner, T. Myles, and E.L. Pryzdial Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway Blood 120 2012 1717 1725
79. C. Esmon Do-all receptor takes on coagulation, inflammation Nat Med 11 2005 475 477 (Pubitemid 40685966)
80. T. Nishimura, T. Myles, A.M. Piliponsky, P.N. Kao, G.J. Berry, and L.L. Leung Thrombin-activatable procarboxypeptidase B regulates activated complement C5a in vivo Blood 109 2007 1992 1997 (Pubitemid 46348197)
81. T. Myles, T. Nishimura, T.H. Yun, M. Nagashima, J. Morser, and A.J. Patterson Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation J Biol Chem 278 2003 51059 51067 (Pubitemid 38020340)
82. M. Delvaeye, M. Noris, A. De Vriese, C.T. Esmon, N.L. Esmon, and G. Ferrell Thrombomodulin mutations in atypical hemolytic-uremic syndrome N Engl J Med 361 2009 345 357
83. H. Wang, I. Vinnikov, K. Shahzad, F. Bock, S. Ranjan, and J. Wolter The lectin-like domain of thrombomodulin ameliorates diabetic glomerulopathy via complement inhibition Thromb Haemost 108 2012 1141 1153
84. C. Zoja, M. Locatelli, C. Pagani, D. Corna, C. Zanchi, and B. Isermann Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice J Immunol 189 2012 3661 3668
85. J.F. Parkinson, C.J. Vlahos, S.C. Yan, and N.U. Bang Recombinant human thrombomodulin. Regulation of cofactor activity and anticoagulant function by a glycosaminoglycan side chain Biochem J 283 1992 151 157
86. C.T. Esmon Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface FASEB J 9 1995 946 955
87. K.T. Preissner, T. Koyama, D. Muller, J. Tschopp, and G. Mullerberghaus Domain-structure of the endothelial-cell receptor thrombomodulin as deduced from modulation of its anticoagulant functions - evidence for a glycosaminoglycan- dependent secondary binding-site for thrombin J Biol Chem 265 1990 4915 4922
88. J. Ye, C.T. Esmon, and A.E. Johnson The chondroitin sulfate moiety of thrombomodulin binds a second molecule of thrombin J Biol Chem 268 1993 2373 2379 (Pubitemid 23057854)
89. S. HajMohammadi, K. Enjyoji, M. Princivalle, P. Christi, M. Lech, and D. Beeler Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis J Clin Invest 111 2003 989 999 (Pubitemid 36397475)
90. G. Mertens, J.J. Cassiman, H. Van Den Berghe, J. Vermylen, and G. David Cell surface heparan sulfate proteoglycans from human vascular endothelial cells. Core protein characterization and antithrombin III binding properties J Biol Chem 267 1992 20435 20443
91. D.H. Atha, J.C. Lormeau, M. Petitou, R.D. Rosenberg, and J. Choay Contribution of 3-O-and 6-O-sulfated glucosamine residues in the heparin-induced conformational change in antithrombin III Biochemistry 26 1987 6454 6461
92. E. Ersdal-Badju, A. Lu, Y. Zuo, V. Picard, and S.C. Bock Identification of the antithrombin III heparin binding site J Biol Chem 272 1997 19393 19400 (Pubitemid 27337735)
93. T. Hashiguchi, S. Mizumoto, Y. Nishimura, J. Tamura, S. Yamada, and K. Sugahara Involvement of human natural killer-1 (HNK-1) sulfotransferase in the biosynthesis of the GlcUA(3-O-sulfate)-Gal-Gal-Xyl tetrasaccharide found in alpha-thrombomodulin from human urine J Biol Chem 286 2011 33003 33011
94. D. Kavanagh, and T. Goodship Genetics and complement in atypical HUS Pediatr Nephrol 25 2010 2431 2442
95. G. Molema, and W.C. Aird Vascular heterogeneity in the kidney Semin Nephrol 32 2012 145 155
96. R.D. Rosenberg, and W.C. Aird Vascular-bed - specific hemostasis and hypercoagulable states N Engl J Med 340 1999 1555 1564 (Pubitemid 29228186)
97. W.C. Aird Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis Crit Care Med 29 2001 S28 S34 [discussion S34-5]
98. M.E. Gerritsen Functional heterogeneity of vascular endothelial cells Biochem Pharmacol 36 1987 2701 2711 (Pubitemid 17135870)
99. T. Stevens, R. Rosenberg, W. Aird, T. Quertermous, F.L. Johnson, and J.G. Garcia NHLBI workshop report: endothelial cell phenotypes in heart, lung, and blood diseases Am J Physiol Cell Physiol 281 2001 C1422 C1433
100. V. Eremina, J.A. Jefferson, J. Kowalewska, H. Hochster, M. Haas, and J. Weisstuch VEGF inhibition and renal thrombotic microangiopathy N Engl J Med 358 2008 1129 1136 (Pubitemid 351398487)
101. A. Richards Glomerular endothelial microvascular heterogeneity and response to cytokines predispose to the development of atypical HUS Mol Immunol 48 2011 1732
102. A.L. Rops, M.J. Van Den Hoven, M.A. Bakker, J.F. Lensen, T.J. Wijnhoven, and L.P. Van Den Heuvel Expression of glomerular heparan sulphate domains in murine and human lupus nephritis Nephrol Dial Transplant 22 2007 1891 1902 (Pubitemid 47244757)
103. A.L. Rops, M. Gotte, M.H. Baselmans, M.J. Van Den Hoven, E.J. Steenbergen, and J.F. Lensen Syndecan-1 deficiency aggravates anti-glomerular basement membrane nephritis Kidney Int 72 2007 1204 1215 (Pubitemid 350059661)
104. D.A. Lauver, and B.R. Lucchesi Sulodexide: a renewed interest in this glycosaminoglycan Cardiovasc Drug Rev 24 2006 214 226 (Pubitemid 46435004)
105. V. Ferro, L. Liu, K.D. Johnstone, N. Wimmer, T. Karoli, and P. Handley Discovery of PG545: a highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis J Med Chem 55 2012 3804 3813
106. X.J. Liang, L. Yuan, J. Hu, H.H. Yu, T. Li, and S.F. Lin Phosphomannopentaose sulfate (PI-88) suppresses angiogenesis by downregulating heparanase and vascular endothelial growth factor in an oxygen-induced retinal neovascularization animal model Mol Vis 18 2012 1649 1657
107. J. Karon, A. Polubinska, A.A. Antoniewicz, K. Suminska-Jasinska, and A. Breborowicz Anti-inflammatory effect of sulodexide during acute peritonitis in rats Blood Purif 25 2007 510 514 (Pubitemid 351194897)
108. F.A. Ofosu Pharmacological actions of sulodexide Semin Thromb Hemost 24 1998 127 138 (Pubitemid 28180822)
109. D.A. Lauver, E.A. Booth, A.J. White, E. Poradosu, and B.R. Lucchesi Sulodexide attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis J Pharmacol Exp Ther 312 2005 794 800 (Pubitemid 40189581)
110. J. Skrha, J. Perusicova, P. Pont'uch, and A. Oksa Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients Diabetes Res Clin Pract 38 1997 25 31 (Pubitemid 27428465)
111. H.J. Lambers Heerspink, M.J. Fowler, J. Volgi, A.T. Reutens, I. Klein, and T.A. Herskovits Rationale for and study design of the sulodexide trials in type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy Diabet Med 24 2007 1290 1295 (Pubitemid 47621802)
112. D.K. Packham, R. Wolfe, A.T. Reutens, T. Berl, H.L. Heerspink, and R. Rohde Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy J Am Soc Nephrol 23 2012 123 130
113. M. Rossini, T. Naito, H. Yang, M. Freeman, E. Donnert, and L.J. Ma Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy Nephrol Dial Transplant 25 2010 1803 1810
114. T.J. Rabelink, H.C. De Boer, and A.J. van Zonneveld Endothelial activation and circulating markers of endothelial activation in kidney disease Nat Rev Nephrol 6 2010 404 414
115. X.L. Chen, S.E. Varner, A.S. Rao, J.Y. Grey, S. Thomas, and C.K. Cook Laminar flow induction of antioxidant response element-mediated genes in endothelial cells. A novel anti-inflammatory mechanism J Biol Chem 278 2003 703 711 (Pubitemid 36790739)
116. S. Mochizuki, H. Vink, O. Hiramatsu, T. Kajita, F. Shigeto, and J.A. Spaan Role of hyaluronic acid glycosaminoglycans in shear-induced endothelium-derived nitric oxide release Am J Physiol Heart Circ Physiol 285 2003 H722 H726
117. M.C. Verhaar, F.E. Strachan, D.E. Newby, N.L. Cruden, H.A. Koomans, and T.J. Rabelink Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade Circulation 97 1998 752 756 (Pubitemid 28135337)